Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 6 Sarcoma 2 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Gynecological Cancer 1 Glioblastoma 1 Craniopharyngioma 1 Carcinoma, Hepatocellular 1 Anlotinib 1 Adenocarcinoma of Lung 1

Interventions

Paclitaxel 6 Carboplatin 6 Radiotherapy 5 Erlotinib Hydrochloride 4 pembrolizumab 3 aldesleukin 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Interleukin-2 2 Cyclophosphamide 2 Bevacizumab 2 veliparib 1 trametinib 1 spartalizumab 1 satraplatin 1 osimertinib 1 onartuzumab 1 nintedanib 1 methyl-4-fluoro-4-deoxyglucose 1 fludarabine phosphate 1 fludarabine 1 bemarituzumab 1 anlotinib 1 aflutinib 1 Taxes 1 Sorafenib 1 Sirolimus 1 Radiotherapy, Conformal 1 Radiosurgery 1 Pentostatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenocarcinoma of Lung × anlotinib × Clear all

NCT04770688 2024-08-15

AUTOMAN

Shanghai Chest Hospital

Phase 1/2 Completed

Adenocarcinoma of Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡